ANNX vs. BMEA, HRTX, KRRO, MRSN, LXRX, NGNE, CRBP, ESPR, PEPG, and RVNC
Should you be buying Annexon stock or one of its competitors? The main competitors of Annexon include Biomea Fusion (BMEA), Heron Therapeutics (HRTX), Korro Bio (KRRO), Mersana Therapeutics (MRSN), Lexicon Pharmaceuticals (LXRX), Neurogene (NGNE), Corbus Pharmaceuticals (CRBP), Esperion Therapeutics (ESPR), PepGen (PEPG), and Revance Therapeutics (RVNC). These companies are all part of the "pharmaceutical preparations" industry.
Annexon (NASDAQ:ANNX) and Biomea Fusion (NASDAQ:BMEA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, community ranking, dividends, profitability and media sentiment.
Annexon presently has a consensus price target of $14.43, indicating a potential upside of 203.76%. Biomea Fusion has a consensus price target of $53.25, indicating a potential upside of 400.00%. Given Biomea Fusion's higher probable upside, analysts plainly believe Biomea Fusion is more favorable than Annexon.
Biomea Fusion is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.
Annexon's return on equity of -66.54% beat Biomea Fusion's return on equity.
Annexon received 9 more outperform votes than Biomea Fusion when rated by MarketBeat users. Likewise, 71.93% of users gave Annexon an outperform vote while only 59.26% of users gave Biomea Fusion an outperform vote.
Annexon has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.33, indicating that its stock price is 133% less volatile than the S&P 500.
96.7% of Biomea Fusion shares are held by institutional investors. 19.1% of Annexon shares are held by insiders. Comparatively, 26.3% of Biomea Fusion shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Annexon had 2 more articles in the media than Biomea Fusion. MarketBeat recorded 6 mentions for Annexon and 4 mentions for Biomea Fusion. Biomea Fusion's average media sentiment score of 1.18 beat Annexon's score of 0.78 indicating that Biomea Fusion is being referred to more favorably in the news media.
Summary
Annexon beats Biomea Fusion on 10 of the 15 factors compared between the two stocks.
Get Annexon News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
